适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
This is clinical study to test, for the first time in people, the safety (anygood or bad effects), how long the drug can stay in the body and if it cancontrol the disease of people diagnosed with advanced cancer that has notresponded to treatment, has returned after it has been treated, or cannotbe treated by surgery, drugs, or any other known treatments.CTIS2023-509969-20-00Celgene Corp.133
进行中（未招募）
1 期
Kidney cancerMetastatic Clear Cell Renal Cell Carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC) and with End-Stage Renal Disease (ESRD)MedDRA version: 21.1Level: PTClassification code: 10050513Term: Metastatic renal cell carcinoma Class: 100000004864MedDRA version: 22.0Level: HLTClassification code: 10038443Term: Renal failure and impairment Class: 10038359CTIS2023-505605-16-00Oncorena AB50
进行中（未招募）
1 期
A Phase 1, Dose Finding Study of CC-92328 in Subjects with Relapsedand/or Refractory Multiple Myeloma.MedDRA version: 21.0Level: LLTClassification code: 10028228Term: Multiple myeloma Class: 10029104Multiple myelomaCTIS2023-505079-65-00Celgene Corp.4
招募中
1 期
A study testing increasing amounts (doses) of CC-91633 to find out what dose can be tolerated without serious side effects in patients with acute myeloid leukemia (AML) that has come back after treatment or cannot be cured or treated by any other known therapies, also called relapsed or refractory AML (R/R AML) and in patients with relapsed or refractory higher-risk myeloid dysplastic syndrome (R/R HR-MDS).Acute myeloid leukemia or myelodysplastic syndrome of high risk group,that has come back after treatment or cannot be cured or treated by anyother known therapies.MedDRA version: 21.0Level: LLTClassification code: 10060558Term: Acute myeloid leukemia recurrent Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10028533Term: Myelodysplastic syndrome Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10081514Term: Acute myeloid leukemia refractory Class: 10029104CTIS2023-503869-34-00Celgene Corp.180
进行中（未招募）
1 期
A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, for the first time in humans.Cardiovascular diseaseCTIS2024-510878-24-00Cereno Scientific AB48